Dr Naris Nilubol (Bethesda, MD): In the in vivo study, if you compare single drug versus combination,
it probably does not have statistical significance in showing lower tumor volume than
the control. So, how would you optimize that? Also, a comment, with your pathway activation
and decreased mammalian target of rapamycin (mTOR) signaling, you might want to look
at autophagy.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: October 04, 2022
Accepted:
July 11,
2022
Identification
Copyright
© 2022 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
